MEDULLOBLASTOMA

This early-phase study tests an oral drug called ONC206 in 102 adults with brain tumors that have come back or are rare. The main goal is to find the safest dose and understand side effects. Participants take the drug by mouth on a weekly schedule, and researchers monitor for any…

This early-phase trial tests a new treatment for children and young adults with medulloblastoma or other rare brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack a protein calle…

This study tests a drug called Lutathera in children and young adults (ages 4 to 39) whose brain tumors have come back or are growing despite treatment. The drug delivers radiation directly to tumor cells that show up on a special PET scan. The goal is to find the safest dose and…

This study tests a drug called PLX038 in adults with brain or spinal cord tumors, especially those with changes in the MYC or MYCN genes. The goal is to see if the drug can shrink tumors or slow their growth. Participants receive the drug through an IV every 3 weeks and are follo…

This early-stage trial tests whether adding the drug ibrutinib to a chemotherapy and immunotherapy combination can help children and young adults (ages 6–25) with brain cancers that have come back or not responded to standard treatment. The study aims to find the safest dose of i…

This study tests if digoxin, a heart medication, can help children and young adults with a specific type of relapsed medulloblastoma (non-WNT/non-SHH). About 23 participants aged 1 to 29 will receive digoxin to see if it slows tumor growth. The goal is to find a new treatment opt…

This early-stage study tests a new treatment for children and young adults (up to age 21) with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target a protein called B7-H3 on tumor cell…

This study tests whether matching treatment to the tumor's genetic makeup can improve outcomes for children under 5 with medulloblastoma. About 130 participants will receive chemotherapy, and some may also get targeted radiation or medication into the spinal fluid. The goal is to…

This study tests a drug called DFMO (eflornithine) as a maintenance therapy to prevent relapse in children with high-risk or relapsed medulloblastoma, a type of brain cancer. About 118 children and young adults up to age 21 will take DFMO after standard treatment. The goal is to …

This study offers expanded access to the drug DFMO for children and young adults (ages 0-30) with rare relapsed tumors like neuroblastoma or medulloblastoma that have certain genetic markers. The goal is to provide treatment when no other options are available, aiming to control …

This study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain cancers (like head and neck, brain, or kidney tumors) that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug i…

This study is testing whether a special type of PET/MRI scan, called 68Ga-DOTATATE, can better detect brain tumors or tell if a tumor has come back after treatment. The study includes 200 adults with certain brain tumors, like meningioma. The goal is to see if this scan gives doc…

This study looks at the long-term health of people who survived medulloblastoma, a type of brain tumor, after receiving radiation to the brain and spine. Researchers want to understand lasting side effects like memory problems, hearing loss, heart issues, and hormone changes. Abo…

This study tests a new approach for children and young adults whose medulloblastoma or ependymoma has come back. Doctors will analyze the tumor's genes and test drugs on it in real time to create a personalized treatment plan. The goal is to see if this can be done quickly enough…